These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37650315)

  • 1. The anti-breast cancer potential of indole/isatin hybrids.
    Wang R; Huang R; Yuan Y; Wang Z; Shen K
    Arch Pharm (Weinheim); 2023 Nov; 356(11):e2300402. PubMed ID: 37650315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of 1H-1,2,3-Triazole-Linked Quinoline-Isatin Molecular Hybrids as Anti-Breast Cancer and Anti-Methicillin-Resistant Staphylococcus aureus (MRSA) Agents.
    Awolade P; Cele N; Ebenezer O; Kerru N; Gummidi L; Gu L; Palma G; Kaur M; Singh P
    Anticancer Agents Med Chem; 2021; 21(10):1228-1239. PubMed ID: 32990543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moxifloxacin-isatin Hybrids Tethered by 1,2,3-triazole and their Anticancer Activities.
    Yang M; Liu H; Zhang Y; Wang X; Xu Z
    Curr Top Med Chem; 2020; 20(16):1461-1467. PubMed ID: 31994464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indole/isatin-containing hybrids as potential antibacterial agents.
    Song F; Li Z; Bian Y; Huo X; Fang J; Shao L; Zhou M
    Arch Pharm (Weinheim); 2020 Oct; 353(10):e2000143. PubMed ID: 32667714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isatin Hybrids and Their Pharmacological Investigations.
    Varpe BD; Kulkarni AA; Jadhav SB; Mali AS; Jadhav SY
    Mini Rev Med Chem; 2021; 21(10):1182-1225. PubMed ID: 33302835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Development in Indole Derivatives as Anticancer Agents for Breast Cancer.
    Kaur K; Jaitak V
    Anticancer Agents Med Chem; 2019; 19(8):962-983. PubMed ID: 30864529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isatin-azole hybrids and their anticancer activities.
    Hou Y; Shang C; Wang H; Yun J
    Arch Pharm (Weinheim); 2020 Jan; 353(1):e1900272. PubMed ID: 31691360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro Evaluation of Isatin Derivatives as Potent Anti-Breast Cancer Agents against MCF-7, MDA MB 231, MDA-MB 435 and MDA-MB 468 Breast Cancers Cell Lines: A Review.
    Chauhan G; Pathak DP; Ali F; Dubey P; Khasimbi S
    Anticancer Agents Med Chem; 2022; 22(10):1883-1896. PubMed ID: 34477529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in isatin hybrids as potential anticancer agents.
    Ding Z; Zhou M; Zeng C
    Arch Pharm (Weinheim); 2020 Mar; 353(3):e1900367. PubMed ID: 31960987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and in vitro cytotoxicity evaluation of novel dihydroartemisinin-isatin hybrids tethered via different length of esters as potential anti-breast cancer agents.
    Xu Z; Pan B; Chen L; Xu D
    Fitoterapia; 2023 Apr; 166():105436. PubMed ID: 36693438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, Synthesis, and Biological Evaluation of Novel Amyl Ester Tethered Dihydroartemisinin-Isatin Hybrids as Potent Anti-Breast Cancer Agents.
    Xu Z; Zhang X; Liu J; Zhao S; Liu J; Zhou W
    Chem Biodivers; 2023 Mar; 20(3):e202201257. PubMed ID: 36808231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis biological evaluation and molecular docking of isatin hybrids as anti-cancer and anti-microbial agents.
    Altamimi M; Syed SA; Tuzun B; Alhazani MR; Alnemer O; Bari A
    J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2288548. PubMed ID: 38073431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanistic insight and structure activity relationship of isatin-based derivatives in development of anti-breast cancer agents.
    Singh A; Singh K; Sharma A; Sharma S; Batra K; Joshi K; Singh B; Kaur K; Chadha R; Bedi PMS
    Mol Cell Biochem; 2024 May; 479(5):1165-1198. PubMed ID: 37329491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indole Derivatives as Anticancer Agents for Breast Cancer Therapy: A Review.
    Sidhu JS; Singla R; Mayank ; Jaitak V
    Anticancer Agents Med Chem; 2015; 16(2):160-73. PubMed ID: 25991424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel ester tethered dihydroartemisinin-3-(oxime/thiosemicarbazide)isatin hybrids as potential anti-breast cancer agents: Synthesis, in vitro cytotoxicity and structure-activity relationship.
    Liu S; Wang S; Xu D; Pan B; Chen L; Zhao S; Xu Z; Zhou W
    Drug Dev Res; 2023 Sep; 84(6):1175-1182. PubMed ID: 37165798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical and pharmacological characterization of isatin and its derivatives: from structure to activity.
    Pakravan P; Kashanian S; Khodaei MM; Harding FJ
    Pharmacol Rep; 2013; 65(2):313-35. PubMed ID: 23744416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current landscape of coumarin hybrids with antibreast cancer therapeutic applications: An updated review.
    Wang R; Chen Z; Huang Y; Zhang Q; Chen M; Huang X
    Arch Pharm (Weinheim); 2024 Oct; 357(10):e2400438. PubMed ID: 38982307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent progress in biologically active indole hybrids: a mini review.
    Mahmoud E; Hayallah AM; Kovacic S; Abdelhamid D; Abdel-Aziz M
    Pharmacol Rep; 2022 Aug; 74(4):570-582. PubMed ID: 35594012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isatin derivatives and their anti-bacterial activities.
    Guo H
    Eur J Med Chem; 2019 Feb; 164():678-688. PubMed ID: 30654239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and biological evaluation of novel morpholinated isatin-quinoline hybrids as potent anti-breast cancer agents.
    Singh A; Kaur H; Arora S; Bedi PMS
    Arch Pharm (Weinheim); 2022 Feb; 355(2):e2100368. PubMed ID: 34783073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.